A supplier suspends shipping to Argentina after 6 consecutive customs detentions
The route did not close because of a rule about peptides.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Stability
Deamidation, oxidation, aggregation and hydrolysis account for nearly all of what happens to a peptide over time. Each has a characteristic residue, a characteristic condition and a characteristic detection problem.
A paragraph on headspace gas composition was added to the list of documentation items after a reader pointed out that the article discussed nitrogen backfill in the section on oxidation and then omitted it from the changes it asked for.
What makes the chemistry worth a reader’s attention is that it is predictable from the sequence. Given a primary structure you can say, without any experiment, which pathways are available and roughly in what order to expect them. An asparagine followed by a glycine is the fastest deamidation motif known. A surface methionine is an oxidation target. A free cysteine is a disulphide problem waiting for oxygen. This is why the same storage conditions produce quite different outcomes for two peptides of similar size, and why generic storage advice is worth so little.
Two methods dominate. Karl Fischer titration determines water specifically, by a stoichiometric reaction with iodine, and is the reference method; the coulometric variant works on the small sample masses a single vial provides. Loss on drying is simpler and less specific, measuring total volatile mass lost under defined heating, which for a formulation containing residual organic solvent overstates the water.
Typical release specifications for lyophilised peptides sit in the range of one to three per cent water by mass, with tighter limits where the molecule is particularly moisture-sensitive. The relationship to stability is not linear. Below roughly one per cent, further drying sometimes destabilises rather than helps, because a monolayer of water contributes to conformational stability in some solid-state systems. Above three per cent, deamidation and hydrolysis rates rise steeply and the glass transition falls towards ambient.
None of the twenty companies the Journal tracks reports residual moisture as a standard release test. Two will provide a figure on request. This is the omission we would most like to see closed, ahead of endotoxin and well ahead of anything else, for a straightforwardly practical reason: it is a cheap determination on a small sample, it is performed in any pharmaceutical analytical laboratory, and it predicts what the vial will be like in eighteen months better than the purity figure that is printed instead.
Deamidation of asparagine proceeds through nucleophilic attack by the backbone nitrogen of the following residue on the asparagine side-chain carbonyl, forming a five-membered succinimide intermediate which then hydrolyses to a mixture of aspartate and isoaspartate, conventionally in a ratio favouring the isomer roughly three to one. Glutamine deamidates by an analogous route, far more slowly, through a six-membered intermediate.
Three factors govern the rate. Sequence is dominant: the residue immediately following the asparagine determines how readily the intermediate forms, and asparagine-glycine is the fastest motif known, with serine, histidine and alanine following. Solution pH matters, with the rate minimal in the mildly acidic region and rising steeply above neutrality as the backbone nitrogen becomes more nucleophilic. Temperature and water activity set the overall pace, which is why the solid state helps so much.
The analytical problem is that isoaspartate has the same elemental composition and therefore the same molecular mass as the parent. Identity confirmation by molecular ion alone cannot distinguish them, and a preparation that is substantially deamidated will present as the intended compound. The isomers usually separate on a sufficiently shallow reversed-phase gradient, and specific methods exist, but only a method designed for the question will find the answer.1
A lyophilised peptide is not stable. It is slow, and its slowness is a manufacturing achievement rather than a property of the molecule.
On what freeze-drying buysMethionine oxidises to the sulfoxide and, under harsher conditions, the sulfone. Tryptophan oxidises through a series of products including kynurenine derivatives. Histidine and tyrosine are susceptible under metal-catalysed conditions, and free cysteine oxidises readily to disulphide. Each of these products differs from the parent by a defined mass increment, which makes oxidation the pathway most reliably detected by mass spectrometry: the sulfoxide is sixteen mass units heavier and unmistakable.
The interesting question is usually where the oxidant came from, and the answers are mundane. Trace transition metals leached from glass, stainless steel or a stopper catalyse oxidation of several residues. Peroxides accumulate in polysorbate surfactants during storage and are a well-documented source of methionine oxidation in formulated products. Dissolved oxygen in the diluent contributes. Light drives it, particularly for tryptophan, and light exposure during handling is entirely undocumented in this trade.
Practical consequences follow that are not obvious. A formulation containing a surfactant that has itself been stored warm for a year may oxidise a peptide that would have been perfectly stable in a plain aqueous vehicle. Headspace composition matters: vials backfilled with nitrogen behave differently from vials sealed under air, and the difference is a manufacturing choice recorded nowhere on the label.2
| Diluent | Composition | Inhibits microbial growth | Chemical interaction risk |
|---|---|---|---|
| Sterile water for injection | Water only | No | None inherent |
| Bacteriostatic water for injection | Water + 0.9% benzyl alcohol | Yes, inhibitory not lethal | Documented aggregation risk with some proteins |
| 0.9% sodium chloride injection | Water + isotonic NaCl | No | Ionic strength effects on some peptides |
| Buffered vehicle | Water + buffer salts | No unless preserved | pH shift on freezing, notably with phosphate |
| Compatibility of any diluent with a given peptide is a question for data on that formulation. Preservative effectiveness is established by a specific compendial test rather than inferred from the presence of a preservative, and preservative content itself declines over an in-use period. | |||
Aggregation covers a range of species from soluble dimers to visible particles, formed by covalent routes such as disulphide scrambling or by non-covalent association of partially unfolded monomers. For peptides the process is often nucleated at an interface — the air-water interface of a shaken vial, the silicone oil layer on a siliconised stopper, the ice-water interface formed during freezing — which is why mechanical handling and freeze-thaw cycling matter as much as temperature.
The analytical difficulty is severe and specific to the trade’s chosen method. Reversed-phase chromatography runs in an acidic, partly organic mobile phase which dissociates most non-covalent aggregates before or during separation. The aggregate is loaded and the monomer is detected. Size-exclusion chromatography under non-denaturing conditions separates by hydrodynamic volume and reports high molecular weight species directly; analytical ultracentrifugation and light scattering methods characterise them further. None of these is offered as a routine service to this market.
The consequence for a reader is that the aggregate content of a research vial is, at present, an unmeasured quantity. It is not necessarily a large one — well-made lyophilised peptides are frequently very low in aggregate — but no certificate in circulation addresses it, and the purity figure that is printed instead is generated by the one method guaranteed not to see it.3
Backbone hydrolysis cleaves an amide bond outright and produces two fragments, each of which is a distinct chromatographic species and each of which is detectable by mass. It is generally slower than deamidation at ordinary storage conditions but becomes dominant at low pH and elevated temperature, which is one reason accelerated stability data for peptides extrapolates so poorly: the pathway that dominates at forty degrees may be irrelevant at five.
Certain positions are much more labile than others. Aspartate-proline and aspartate-glycine bonds hydrolyse relatively readily under acidic conditions. N-terminal glutamine can cyclise to pyroglutamate, losing ammonia. Peptides with an N-terminal sequence of the right geometry can form a diketopiperazine and shed the first two residues as a cyclic dipeptide, a route that is fast enough at neutral pH to matter for some sequences.
Racemisation at susceptible residues produces epimers that are chemically identical in composition and differ only in stereochemistry. They are among the hardest impurities to detect, requiring either a chiral method or a sufficiently discriminating reversed-phase separation, and they are essentially never reported. A vial can be nominally pure by every measurement on its certificate and contain a percentage of a diastereomer with unknown biological behaviour.
A stability study is only as good as the analytical method behind it, and the requirement has a name: the method must be stability-indicating, meaning it must resolve the parent compound from its degradation products and quantify the change. Establishing that is done by forced degradation — deliberately stressing the material with acid, base, oxidant, heat and light — and demonstrating that the resulting products are separated from the parent and from each other with adequate peak purity.
Almost nothing sold as a purity determination in this market has been validated that way. A generic peptide gradient run for twelve minutes may perfectly well resolve the parent from its two largest process impurities and entirely fail to resolve it from its isoaspartate isomer or a closely related oxidation product. The number it returns is a purity figure, not a stability measurement, and using a series of such figures to argue that a product has not degraded is a category error.
The compendial guidance on analytical validation is explicit about specificity, and about demonstrating it against the degradation products the molecule can actually form. The gap between that expectation and practice in this trade is not a matter of dishonesty. It is that the method being sold was designed for a different purpose and is being asked a question it was not built to answer.4
The temptation with any stability programme is to run the accelerated condition, fit an Arrhenius relationship to the rate constants, and extrapolate to the intended storage temperature. For a single reaction with a temperature-independent mechanism that is sound. For peptides it frequently is not, and the reason is that different pathways have different activation energies.
Suppose a peptide degrades at five degrees principally by deamidation and at forty degrees principally by hydrolysis, with the second having a higher activation energy. Measuring total degradation at forty degrees measures mostly hydrolysis; extrapolating that rate down to five degrees predicts almost nothing about the deamidation that will actually dominate. Aggregation is worse still, because it is frequently nucleated by interfaces and mechanical stress rather than by thermal energy alone, and does not obey a simple temperature relationship at all.
The practical rule the Journal applies when reading a stability claim is to ask what condition the data was generated at and whether the degradation products were identified as well as quantified. Accelerated data that shows which products form is genuinely useful as a warning of what to watch for. Accelerated data reduced to a single percentage and extrapolated to a shelf life is a projection dressed as a measurement, and for this class of molecule it is a poor projection.
Isoaspartate has the same mass as the parent. A laboratory confirming identity by molecular ion alone will report a degraded preparation as the intended compound.
On deamidationPhotostability has its own guideline, its own defined light source options and its own exposure requirement expressed in lux hours of visible light and watt hours per square metre of near ultraviolet. Products are tested in the immediate container, and where they fail, in the marketing pack, and where they fail again the label carries a protection instruction. The chemistry is real: tryptophan and tyrosine absorb in the near ultraviolet and photo-oxidise, and photolytic disulphide cleavage is well documented.
Nothing about light exposure is recorded anywhere in the research-peptide supply chain. Vials are frequently supplied in clear glass. Photographs for listings are taken under studio lighting. Parcels are opened on kitchen counters. A reconstituted vial may sit on a shelf under a window for weeks. The cumulative exposure is unknown and unknowable, and it is plausibly a larger contributor to degradation than the transit excursions that attract all the attention.
The Journal makes one narrow observation rather than a recommendation, because recommendations are not this publication’s business. Amber glass, or a secondary carton, costs a fraction of a cent per unit and removes an uncontrolled variable entirely. Several of the twenty companies we track already ship in amber vials; most do not, and the ones that do not have not, as far as we can establish, generated any data suggesting it does not matter.5
| Intended storage | Long-term condition | Intermediate | Accelerated |
|---|---|---|---|
| Room temperature | 25 °C / 60% RH, ≥12 months | 30 °C / 65% RH | 40 °C / 75% RH, 6 months |
| Room temperature, hot climatic zone | 30 °C / 65% RH, ≥12 months | not applicable | 40 °C / 75% RH, 6 months |
| Refrigerated | 5 °C ± 3 °C, ≥12 months | not applicable | 25 °C / 60% RH, 6 months |
| Frozen | −20 °C ± 5 °C, ≥12 months | not applicable | single-batch excursion study |
| Below −20 °C | case by case | not applicable | single-batch excursion study |
| Summarised from the harmonised guideline on stability testing of new drug substances and products. Frozen-storage products are not accelerated in the usual sense; the guidance substitutes a study of the effect of a short excursion above the intended condition, which is precisely the data a shipped research vial would need and does not have. | |||
Mean kinetic temperature is defined through the Arrhenius relationship: it is the temperature which, held constant, would produce the same degradation as the actual varying profile. Computing it requires converting each temperature to a rate through an exponential, averaging the rates, and converting back. The activation energy conventionally assumed for the purpose is around eighty-three kilojoules per mole, which is a compromise value rather than a property of any particular molecule.
The consequence is easiest to see in an example. A profile spending ninety hours at four degrees and six hours at thirty-eight degrees has an arithmetic mean of about six degrees. Its mean kinetic temperature, computed with the conventional activation energy, comes out several degrees higher, because the six hot hours contribute far more to the exponentially weighted average than their share of the elapsed time. Reporting the arithmetic mean of such a profile is not merely imprecise; it discards exactly the information the calculation exists to capture.
This is why the compendial definition of controlled room temperature is expressed both as a range and as a mean kinetic temperature not exceeding twenty-five degrees, and why any shipment assessment that quotes only an average should be read with suspicion. The original derivation of the working formula is now more than fifty years old and remains the basis of the calculation in current use.67
The regulatory framework in this article is taken from the harmonised guidelines on stability testing and on biotechnological products, read in the original, and from the current compendial chapters on storage definitions, distribution of temperature-sensitive products and stability in dispensing practice. The degradation chemistry is drawn from the peptide and pharmaceutical sciences literature, and where a claim is a generalisation across sequences this piece says so, because sequence dependence is the rule rather than the exception.
The shipment data is ours. Nine parcels, ordered at catalogue prices as ordinary customers, with calibrated loggers placed inside the insulated payload and sampling at five-minute intervals. Eight complete traces and one truncated by a customs hold. We disclose that nine parcels is not a survey, that we did not control the packing operation, and that a single logger cannot characterise a payload with a thermal gradient across it.
Nothing in this department is a recommendation about storing, reconstituting or administering anything. The compounds discussed are sold for research use only and are not approved for human use in any jurisdiction. Corrections and disputes go to standards@compoundjournal.com; documents, traces and certificates readers would like examined go to letters@compoundjournal.com, and we do not identify the source of anything sent to us.
The finding the Journal least wanted and most trusts is that the transit excursions everybody worries about are probably not the largest exposure in this supply chain. A dried cake at low moisture tolerates a warm afternoon. A reconstituted vial in a refrigerator door for six weeks, with no in-use study behind the number that justified the six weeks, is a different proposition, and it attracts almost no attention at all.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
Your table of degradation pathways lists racemisation and then says it is essentially never reported. If it is never reported, on what basis do you list it as a real risk rather than a theoretical one?
— C. Adeoti, Ibadan
On the basis of the synthesis and analytical literature, where epimer formation during solid-phase assembly and during storage at extremes of pH is well characterised. What is missing is not evidence that it occurs but evidence about how much of it is present in any particular commercial vial, which is a different absence and the one we should have named.
The mean kinetic temperature explanation is the clearest I have read anywhere, including in the training my employer paid for. I have printed the sidebar and put it on the wall of the dispatch room.
— R. Anand, Pune
You say no company reports residual moisture. I obtained a figure from a supplier last year without difficulty, on request, so the data exists in at least some cases. The problem may be less that it is not measured than that it is not printed.
— D. Ramkissoon, Port of Spain
I have shipped temperature-sensitive material commercially for eleven years and your coolant arithmetic is right but generous. You assume the pack starts fully frozen. In practice packs are pulled from a freezer that is opened forty times a day, and a pack that starts at minus four with a soft core has lost a fair share of its budget before the box is closed.
— P. Kovalenko, Lviv
A good point and one we had not considered properly. The latent heat calculation assumes a fully solid pack at its melting point, and a partially thawed pack is exactly as much worse as the missing solid fraction. We have added a sentence and would welcome any data you can share on pack condition at packing.
I would add one omission to your list. Nobody states the headspace gas. Nitrogen-backfilled vials and air-sealed vials behave differently for any oxidation-prone sequence, and it is a single word on a certificate.
— R. Whitlam, Adelaide, SA
The route did not close because of a rule about peptides.
Skin thickness at the standard injection sites is approximately two millimetres in adults and varies remarkably little with body mass. That single finding is why short…
Reversed-phase chromatography runs in an organic, acidic mobile phase that dissociates most non-covalent aggregates on the way to the detector.
The route did not close because of a rule about peptides.
What the renal and hepatic outcome programmes actually measured, and over what duration.
What the renal and hepatic outcome programmes actually measured, and over what duration.